Solventum Corp (SOLV) stock
SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3094% above fair value
$88.81+0.19 (+0.21%)
Close on Nov 12, 2026Market cap $15.12BP/E 99.8Yield –
Solventum r&d expenses
Research and development expenses are spending on new products and technology.
Solventum's R&D Expenses for the twelve months ending Sep 30, 2026 was $723.00M, down 5.4% year over year. For fiscal 2025 it was $739.00M, down 4.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $739.00M | -4.6% |
| FY2024 | Dec 31, 2024 | $775.00M | +2.2% |
| FY2023 | Dec 31, 2023 | $758.00M | -1.2% |
| FY2022 | Dec 31, 2022 | $767.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $181.00M | -1.1% |
| Q2 FY2026 | Jun 30, 2026 | $178.00M | -5.8% |
| Q1 FY2026 | Mar 31, 2026 | $189.00M | -2.1% |
| Q4 FY2025 | Dec 31, 2025 | $175.00M | -12.1% |
| Q3 FY2025 | Sep 30, 2025 | $183.00M | -3.2% |
| Q2 FY2025 | Jun 30, 2025 | $189.00M | -1.6% |
| Q1 FY2025 | Mar 31, 2025 | $193.00M | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $199.00M | +4.7% |
| Q3 FY2024 | Sep 30, 2024 | $189.00M | +5.0% |
| Q2 FY2024 | Jun 30, 2024 | $192.00M | -0.5% |
| Q1 FY2024 | Mar 31, 2024 | $195.00M | 0.0% |
| Q4 FY2023 | Dec 31, 2023 | $190.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $180.00M | – |
| Q2 FY2023 | Jun 30, 2023 | $193.00M | – |
| Q1 FY2023 | Mar 31, 2023 | $195.00M | – |
See a number that looks wrong?